|1.||Sodroski, Joseph: 3 articles (01/2014 - 04/2009)|
|2.||Haim, Hillel: 3 articles (01/2014 - 04/2009)|
|3.||Hahn, Beatrice H: 3 articles (07/2013 - 05/2005)|
|4.||Shaw, George M: 3 articles (07/2013 - 05/2005)|
|5.||Wang, C R: 3 articles (10/2000 - 06/2000)|
|6.||Salazar-Gonzalez, Jesus F: 2 articles (07/2013 - 03/2012)|
|7.||Haynes, Barton F: 2 articles (07/2013 - 03/2012)|
|8.||Salazar, Maria G: 2 articles (07/2013 - 03/2012)|
|9.||Kwong, Peter D: 2 articles (09/2009 - 05/2005)|
|10.||Wang, Liping: 2 articles (09/2009 - 04/2009)|
08/01/2007 - "As use of CXCR4 improved, infection mediated by the mutated envelopes became more resistant to soluble CD4 inhibition and direct binding to CD4 increased. "
01/01/2012 - "Although soluble CD4 (sCD4) can inactivate laboratory-adapted HIV-1 strains, it fails to reduce the viral loads in clinical trials because of its low potency against primary isolates and tendency to enhance HIV-1 infection at low concentration. "
10/01/2003 - "In studies using soluble CD4 (sCD4) to inhibit infection, wild-type and Nef-defective HIV-1 escaped the sCD4 block with similar kinetics. "
08/01/1990 - "Our studies show that the CD4 receptor is required for antibody-mediated enhancement of infection, as enhancement can be blocked by recombinant soluble CD4 and by Leu3 antibody. "
07/01/2013 - "We did not observe a consistent difference either in heterologous neutralization sensitivity or in sensitivity to soluble CD4 between the two groups, suggesting similar conformations between viruses from acute and chronic infection. "
|2.||Acquired Immunodeficiency Syndrome (AIDS)
01/01/2009 - "Neutralization assays using pseudotyped viruses showed an association between the capacity of HIV to enter macrophages and increased sensitivity to the broadly neutralizing monoclonal antibody (mAb) b12, which recognizes a conserved epitope overlapping the CD4 binding site, but not sensitivity to soluble CD4 (sCD4) or b6, a non-neutralizing CD4 binding site mAb. Furthermore, loss of an N-linked glycosylation site at position 386 in the V4 region of Env enhanced macrophage tropism together with b12 sensitivity, but not neutralization by sCD4, b6, or a broadly neutralizing AIDS patient serum. "
07/01/1996 - "The destruction of normal CD4 T cells by monocytes from AIDS patients can be blocked by soluble CD4 and by free gp120. "
03/01/1992 - "Soluble CD4 (sCD4), a recombinant truncated form of CD4, has been shown to inhibit HIV-1 in vitro and is being tested as a therapy for AIDS. "
03/01/1992 - "Correlation between kinetics of soluble CD4 interactions with HIV-1-Env-expressing cells and inhibition of syncytia formation: implications for mechanisms of cell fusion and therapy for AIDS."
06/01/1991 - "We have utilized the simian immunodeficiency virus of macaques (SIVmac)-infected rhesus monkeys to explore another possible therapeutic application of CD4 in AIDS--the use of recombinant soluble CD4 (rsCD4) as an immunogen. "
|3.||AIDS-Related Complex (ARC)
02/15/1990 - "To study the safety and pharmacokinetics and to derive preliminary evidence on surrogate indicators of efficacy of recombinant soluble CD4 (rsCD4) in patients with the acquired immunodeficiency syndrome (AIDS) and advanced AIDS-related complex. "
02/15/1990 - "Recombinant soluble CD4 is well tolerated by patients with AIDS or advanced AIDS-related complex. "
02/15/1990 - "Recombinant soluble CD4 therapy in patients with the acquired immunodeficiency syndrome (AIDS) and AIDS-related complex. "
02/15/1990 - "The safety and pharmacokinetics of recombinant soluble CD4 (rCD4) in subjects with the acquired immunodeficiency syndrome (AIDS) and AIDS-related complex. "
01/01/1990 - "Circulating soluble CD4 (sCD4) levels were measured in 20 patients (11 with the acquired immunodeficiency syndrome [AIDS] and 9 with AIDS-related complex [ARC]) treated with azidothymidine (AZT) and in 12 patients (nine with AIDS and three with ARC) who were in the placebo group. "
|4.||Acute Myeloid Leukemia (Acute Myelogenous Leukemia)
01/01/1996 - "The mutual correlation among soluble CD4 (sCD4), soluble CD8 (sCD8), and soluble CD23 (sCD23) has not yet been studied in patients with rheumatoid arthritis (RA), although previous studies have demonstrated that certain soluble markers of immune activation are elevated in RA. "
11/01/2001 - "We investigated the concentration of soluble CD4 molecules (sCD4) in serum, and the mechanism of sCD4 production from T lymphocytes, in patients with rheumatoid arthritis (RA). "
11/01/2001 - "Increased soluble CD4 molecules and the role of soluble CD4 production in patients with rheumatoid arthritis."
07/01/1991 - "Soluble CD4 in patients with rheumatoid arthritis and osteoarthritis."
01/01/2013 - "Increased soluble CD4 in serum of rheumatoid arthritis patients is generated by matrix metalloproteinase (MMP)-like proteinases."
|2.||Interleukin-2 Receptor alpha Subunit
|7.||beta 2-Microglobulin (beta 2 Microglobulin)
|9.||Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)
|10.||Interferon-gamma (Interferon, gamma)